Notice of Extraordinary General Meeting 2 Nov, 2005

This press release may not be distributed or disclosed in the United States, Canada, Australia, New Zealand, Japan, or any other country where such distribution or public disclosure presumes further measures than what follows from Swedish law, nor is the invitation to subscribe for shares aimed at people in such countries. The shareholders in BioInvent International AB (publ), reg no 556537-7263, are hereby invited to attend the Extraordinary General Meeting to be held at 4 p.m. on Wednesday 2 November at Ideon, Sölvegatan 41 in Lund. A. RIGHT TO ATTEND Shareholders who wish to attend the General Meeting shall be recorded in a print-out of the share register maintained by the Swedish Securities Register Centre ("VPC") as of Friday 21 October 2005 and notify BioInvent of their intention to participate in the General Meeting at the address Sölvegatan 41, 227 70 Lund, att: Marie Serwe, or by telefax +46 46 211 08 06 or by phone +46 46 286 85 50, or by e-mail marie.serwe@bioinvent.com by 4 p.m. on Thursday 27 October 2005 at the latest. In order to be entitled to participate in the General Meeting, shareholders with nominee-registered shares should request their bank or broker to have their shares temporarily owner-registered with the VPC. Such registration must be made on Friday 21 October 2005 at the latest and the nominee should therefore be notified in due time before said date. Shareholders represented by proxy should attach papers of authorization to the notification of attendance. A person, who represents a legal person, shall submit a copy of the registration certificate or corresponding documents of authorization showing the signatories for the firm. B. MATTERS TO BE DEALT WITH AT THE MEETING Proposal for agenda 1. Opening of the meeting 2. Election of chairman of the meeting 3. Preparation and approval of the voting list 4. Election of two minutes-checkers 5. Determination of compliance with the rules of convocation 6. Approval of the agenda 7. Presentation of a copy of the latest annual report and the auditor’s report and the report of the Board of Directors according to the Companies Act, Chapter 4 Section 4 and the statement of the auditor on the report 8. Approval of the resolution of the Board of Directors to issue new shares 9. Closing of the meeting Proposal for the approval of the resolution of the Board of Directors to issue new shares (item 8) On 12 October 2005, the Board of Directors resolved, subject to the approval of the General Meeting, to issue a total of maximum 17,685,333 new shares with a nominal value of SEK 0.50 (50 öre), with preferential rights for the shareholders of the company. The record day for receiving subscription rights shall be 10 November 2005 whereby five old shares will entitle to subscription to three new shares. The subscription price for each share shall be SEK nine (9). The period of subscription shall be from 5 November up to and including 2 December 2005, with a right for the Board of Directors to prolong the subscription period. In the event that not all of the shares are subscribed for by exercise of subscription rights, the Board shall resolve to allocate shares for subscription without subscription rights up to the maximum amount of the share issue. In such case, priority will be given firstly to existing shareholders who have subscribed for shares for the full amount of subscription rights received and who wish to subscribe for additional shares, pro rata in relation to the number of shares subscribed for using subscription rights; secondly to others who are not shareholders but who have subscribed for shares by the exercise of subscription rights and who wish to subscribe for additional shares, pro rata in relation to the number of shares subscribed for using subscription rights; and thirdly to other parties who have notified the Company of their interest in subscribing for shares without subscription rights, pro rata in relation to such subscription made, with priority being given to parties who have provided guarantees or have signed letters of intent for the subscription of shares without subscription rights; and fourthly to parties who have provided guarantees or have signed letters of intent for the subscription of shares without subscription rights, according to the terms and conditions for such guarantees and letters of intent. The Board of Directors recommends the General Meeting to approve of the resolution of the Board of Directors. C. AVAILABLE DOCUMENTATION The annual report and documents according to the Companies Act and the complete proposal of the Board of Directors will be accessible at the company in Lund and on the company’s website www.bioinvent.se and will be forwarded automatically and free of charge to shareholders, who intend to participate in the general meeting and to other shareholders upon request. _______________ Lund in October 2005 The Board of Directors BIOINVENT INTERNATIONAL AB (PUBL) For more information BioInvent International AB Svein Mathisen Cristina Glad President & CEO Vice President Tel.: +46 (0)46-286 85 67 Tel: +46 (0)46-286 85 51 Mobile: +46 (0)708-97 82 13 Mobile: +46 (0)708-16 85 70 e-mail: svein.mathisen@bioinvent.com e-mail: cristina.glad@bioinvent.com Notes to editors: BioInvent International AB, which is listed on the O list of the Stockholm Stock Exchange (BINV), develops therapeutic antibodies against diseases where there is a significant unmet medical need. Antibodies are a strongly growing segment of the pharmaceutical market. BioInvent focuses on discovery and development of therapeutic antibodies, and documents their effect in pre-clinical and early clinical trials. Clinical development, marketing and distribution are conducted in cooperation with established pharmaceutical companies. Today BioInvent conducts innovative drug projects involving conditions such as HIV infection, thrombosis, cancer, atherosclerosis and diseases of the joints. These projects are based on a competitive technology platform that covers the entire chain from the n-CoDeRÒ antibody library for fast and efficient selection of human antibodies, to production in a facility fully approved for manufacturing biological drugs. The scope and strength of this platform is also utilised by partners in the development of new drugs. These partners include ALK-Abelló, Antisoma, Celltech, GlaxoSmithKline, Igeneon, ImmunoGen, OrbusNeich and XOMA. The Company, which currently has 92 employees, is located at Ideon in Lund. BioInvent International AB (publ) Co. reg. no. 556537-7263, Address: Sölvegatan 41 Mailing address: 223 70 LUND Tel: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com

About Us

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR and the screening tool F.I.R.S.T. are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

Subscribe

Documents & Links